sentence: 4 In current clinical practice , there are two EGFR-targeting strategies employing monoclonal antibodies directed at the extracellular domain of the receptor , and small molecule , ATP tyrosine kinase inhibitors.5 ,6 The use of both modalities in the treatment of squamous cell cancer of the head and neck ( SCCHN ) is currently under investigation.7 ,8 Cetuximab .